Neurotech Shareholders Back All AGM Resolutions
NTI: $0.017 +6.25% · MC: $31M
Neurotech International shareholders passed all resolutions put to a poll at the annual meeting, including director elections, placement-related approvals and options issues. The company’s latest quarterly update said its pivotal Phase 3 autism trial had begun dosing and it had secured funding intended to support development through the trial’s top-line results.

Comments